In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.
The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.
AstraZeneca and Aptamer Group will collaborate to leverage Aptamer’s platform for targeted delivery of oligonucelotides to the kidney for therapeutic development.
Sanofi has written to the UK’s health secretary and the chief executive of the NHS to inform them that the company is stockpiling drugs ahead of the deadline for Brexit.
Roche, Merck and Lilly are among those calling for regulatory harmonisation and free movement of goods between the EU and the UK once the latter leaves the Union.
Following the announced sale of AstraZeneca’s solid dose facility to Avara, the former outlines the Reims, France-based sites capabilities, and tells us why it is letting it go.
Recipharm will make clinical trial capsules to support oncology candidate KAND567, a former AstraZeneca Fractalkine receptor inhibitor being developed by Kancera.
AstraZeneca has committed A$100m ($76.4m) to expand its manufacturing facility in Sydney Australia, citing growing demand for asthma medications in China.
Industry group the ABPI has called on the next UK Government to support local drug production, increase National Health Service (NHS) funding and put life sciences at the heart of its post-Brexit plan.
AstraZeneca will supply Toprol-XL to Aralez Pharmaceuticals Trading for at least 10 years after selling the US rights to the off-patent beta blocker for $175m.
Biocon, an Indian biopharmaceuticals company, has received European approvals for its Rosuvastatin Calcium, a generic equivalent of AstraZeneca’s Crestor tablets.
With an eye on early-phase research, AstraZeneca has signed two deals – a five-year agreement to gain access to PatientsLikeMe’s network, and a three-year alliance with the Lead Discovery Center.
An AstraZeneca API plant in Bristol, UK will close its doors within two years due to patent expirations of its cholesterol-lowering blockbuster Crestor.
AstraZeneca has continued the Big Pharma trend away from small molecule blockbusters and towards a biologics-heavy pipeline, announcing the closure of its Pulmicort facility in Massachusetts.
Pharma companies have called on the Swedish government to prevent manufacturing going the way of R&D and leaving the country, after AstraZeneca closed its research in Lund in 2012.
Expert advice was key to persuading AstraZeneca to build a £120m ($188m) manufacturing plant in the UK according to the MHRA, which says the same help is available to all drugmakers free of charge.
The opening of a global IT centre in India will bring services back in-house, but AstraZeneca says it is not changing its outsourcing strategy for R&D and manufacturing.
Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist (LAMA/LABA) fixed dose combination respiratory drug following the latter’s acquisition of Almirall.
Pfizer will keep a “substantial” level of manufacturing in the UK if it takes over AstraZeneca, said the CEO in a letter to the country’s Prime Minister.
AstraZeneca has chosen big data and analytics services provider Sinequa, to index millions of R&D documents for use in a search platform providing “sub-second” answers to research questions.
With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.
Injectable device manufacturer Unilife has announced a contract with a pharmaceutical multinational for the use of its Ocu-ject eye syringe, marking its fifth major contract in four months.
Computational biology firm Blackfield has won its fourth Big Pharma contract in a year, with Anglo-Swedish drugmaker AstraZeneca signing up for its genomics services
The US Department of Justice’s Attorney’s Office in Boston has sent subpoenaed documents related to AstraZeneca's UK manufacturing practices, which the company said it is complying with.
Bristol-Myers Squibb (B-MS) will continue to make the OTCs it licensed to Reckitt Benckiser for the time being but will hand over manufacturing if the UK drugmaker buys them outright.
A new personalised medicine-focused partnership for AstraZeneca, expansion in three continents for World Wide clinical and six small CROs team-up to create one super-team. Outsourcing-pharma.com presents a round-up of the latest in clinical research services.
Wuxi AppTec expects to add capacity as needed to service the partnership it formed with MedImmune and is comfortable with the level of investment required.
in-PharmaTechnologist presents its round-up of the latest career moves within the pharmaceutical industry, including news from Eli Lilly, Roche, and Merck.